Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(5):410; doi:10.1093/jnci/95.5.410
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Belda-Iniesta, C.
Right arrow Articles by Barón, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Belda-Iniesta, C.
Right arrow Articles by Barón, M. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 5, 410, March 5, 2003
© 2003 Oxford University Press

CORRESPONDENCE

Re: Folliculitis Associated With Weekly Paclitaxel Treatment

Cristobal Belda-Iniesta, Enrique Casado, Miriam Corral de la Calle, Beatriz Castelo, Manuel González Barón

Affiliations of authors: C. Belda-Iniesta, E. Casado, B. Castelo, M. González Barón (Medical Oncology División), M. Corral de la Calle (Dermatology División), Hospital Universitario La Paz, Universidad Autónoma de Madrid, Madrid, Spain.

Correspondence to: Manuel Gonzalez-Baron, M.D., Ph.D., Servicio de Oncología Médica, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain (e-mail: mgonzalezb.hulp@salud.madrid.org).

The first 10% of the full text of this article appears below.

Chemotherapy can cause different cutaneous toxicities usually masked by the underlying life-threatening malignancy or treatment-associated complications. Here we describe the first two known cases of paclitaxel-related folliculitis. The first case occurred in a 55-year-old white male with 5-fluorouracil (5-FU)/cisplatin refractory disseminated epidermoid esophageal cancer, who received weekly paclitaxel (150 mg/m2 on days 1, . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?